>>Business

Pipeline Catalysts Key Focus For Roche’s H1 Update

Swiss Pharma’s Increasing Diversification Also Big Theme

15 Jul 2021

• By Sten Stovall

Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.

Roche focus is growing therapeutic diversity, with multiple products and combinations • Source: Alamy

While Roche Holding AG remains synonymous with oncology, its early pipeline is now diversifying into other areas that offer fresh opportunity to discover truly innovative therapies, and it is this narrative that investors will be especially keen to explore when the Swiss drug maker reports its half-year update on 22 July.

Analysts generally agree Roche has so far done well managing the sales decline caused by biosimilar competition to its legacy...